Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Regulatory update – GSK announces submission of albiglutide BLA to the US FDA for the treatment of type 2 diabetes
GSK announced a regulatory submission to the FDA for albiglutide, an investigational treatment for adult patients with type 2 diabetes.
-
GSK and Theravance announce regulatory submission for ANORO™ (UMEC/VI) in Europe
GSK & THRX announced submission of regulatory application in the EU for the LAMA/LABA combination medicine for patients with COPD
-
GSK and Theravance announce regulatory submission for UMEC/VI (LAMA/LABA) in the US
GSK & THRX announced submission of regulatory application in US for LAMA/LABA combination medicine, UMEC/VI, for patients with COPD.
-
FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US
GSK announced ,FDA has approved FLUARIX QUADRIVALENT Influenza Vaccine for the immunisation of patients to help prevent seasonal influenza
-
Results from five phase III studies presented for GSK’s two candidate quadrivalent influenza vaccines
GSK announced results from five Phase III studies investigating two candidate quadrivalent influenza vaccines. presented in Spain & US.
-
GSK announces further initiatives to advance openness and collaboration to help tackle global health challenges
GSK CEO Sir Andrew Witty will outline new steps to build on progress resulting from open innovation approach to R&D.
-
Millions of children in Pakistan to be protected against pneumococcal disease with GSK’s Synflorix
GSK & GAVI Alliance pneumococcal vaccine, SynflorixTM, is to be introduced into the national immunisation programme in Pakistan.
-
Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV
Shionogi-ViiV announced phase III data required for initial regulatory filings of dolutegravir in adults infected with HIV are in house.
-
GSK and Theravance announce FDA acceptance of FF/VI New Drug Application (NDA) submission in the US for COPD
GSK & THRX announced New Drug Application for vilanterol for patients with COPD, has been accepted by the FDA meaning it's ready for review.
-
GlaxoSmithKline plc announces changes to its Board and Committees
GlaxoSmithKline plc today announces the following changes to its Board and Committee structure.
-
Regulatory Update: GSK announces submission for a new indication for Synflorix™ in Europe
GSK submitted a regulatory application in EU seeking approval of Synflorix, a Streptococcus pneumococcal vaccine for infants and children.
-
GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash
GSK announces that it has acquired 5Mil newly issued shares of Response Genetics Inc. common stock at a price of US$1.10 per share in cash.
-
GSK and Theravance announce completion of the Phase III programme for once-daily LAMA/LABA (UMEC/VI) in COPD
GSK & THRX announced completion of phase III programme of LAMA/LABA involving approx. 6,000 patients with COPD.
-
GSK announces start of Phase III programme of sirukumab in rheumatoid arthritis
GSK & Janssen announced, Phase III programme evaluating sirukumab, (IL)-6 monoclonal antibody in the treatment of RA, has commenced dosing.
-
GlaxoSmithKline reaches agreement to divest majority of Classic Brands in Australia for £172m
GSK announced it's reached agreement to divest majority of its Classic Brands in Australia to Aspen for approximately £172 million in cash.
-
European Commission grants marketing authorisation for pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes
GSK announced today the EC has granted pazopanib marketing authorisation for the treatment of aSTS who have received prior chemotherapy.
-
Regulatory update – GSK announces submissions in the EU and US for dabrafenib and trametinib
GSK announced submissions in EU & US related to single-agent use of dabrafenib & trametinib to treat BRAF V600 mutation metastatic melanoma.
-
GSK completes acquisition of Human Genome Sciences
GSK announced it has completed acquisition of HGS for US$3.6 billion equity. outstanding shares acquired for US$14.25 per share in cash.
-
GSK announces acquisition of 79% of Human Genome Sciences shares; commences subsequent offering period
GlaxoSmithKline plc (LSE: GSK) today announced the results of its initial tender offer for all outstanding shares of Human Genome Sciences.
-
Maximuscle powers Vodafone McLaren Mercedes drivers through the 2012 Formula 1™ season
Leading sports nutrition brand continues its presence with on-car logos in Hungary
